MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Impact · against what's priced in

MannKind shares have a positive catalyst as new data confirms Furoscix ReadyFlow's efficacy is comparable to the IV gold standard, significantly expanding its potential outpatient market. While the FDA approval is already reflected in the price, the clinical evidence supporting flexible administration and parity with the On-body Infusor provides a fundamental basis for higher revenue projections.

Scored by the NIS engine · methodology.

• biotech
• clinical trials
• drug delivery